Figure 2. FBXO28 overexpression increases pancreatic cancer cell proliferation. (A) Lentiviral transfection to form stable cells (negative control [NC], FBXO28, Control, shFBXO28#1, shFBXO28#2) and qRT-PCR and western blot to verify transfection effectiveness. (B–E) Cell Counting Kit-8 (CCK-8), EdU, and clone plate experiments were used to identify the capacity of FBXO28 for cell proliferation and formation in pancreatic cancer cells. (F–H) Western blot and flow cytometry to investigate the effect of FBXO28 on the cell cycle. (I) To construct a xenograft model, mice were injected subcutaneously with cells according to grouping, tumor volume was assessed weekly, the mice were euthanized after 6 weeks, and the tumors were resected and weighed. (J) Immunohistochemical (IHC) of mouse tumor tissues showing the protein expression of Ki67 and proliferating cell nuclear antigen (PCNA) (magnification: ×200, ×400). **P < 0.01, ***P < 0.001, ****P < 0.0001.